Sai Life Sciences · NSE: SAILIFE · BSE: 544306
Q1 FY27 results · Apr–Jun 2026
Sai Life Sciences reported revenue from operations of ₹554.28 crore (up 11.7% from Q1 FY26) and net profit of ₹73.28 crore (up 21.2% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 554.28 | 496.42 | +11.7% | 602.14 | −7.9% |
| Other income | 3.54 | 9.90 | −64.2% | 15.52 | −77.2% |
| Total income | 557.83 | 506.32 | +10.2% | 617.66 | −9.7% |
| Profit before tax | 97.97 | 80.75 | +21.3% | 139.23 | −29.6% |
| Net profit for the period | 73.28 | 60.45 | +21.2% | 104.24 | −29.7% |
| EPS, basic (₹) | 3.46 | 2.90 | +19.3% | 4.93 | −29.8% |
| Net margin (%) | 13.2 | 12.2 | 17.3 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 546.73 | 483.04 | +13.2% | 594.34 | −8.0% |
| Other income | 3.54 | 10.01 | −64.6% | 15.74 | −77.5% |
| Total income | 550.27 | 493.04 | +11.6% | 610.09 | −9.8% |
| Profit before tax | 95.33 | 77.98 | +22.3% | 136.85 | −30.3% |
| Net profit for the period | 71.34 | 58.37 | +22.2% | 102.53 | −30.4% |
| EPS, basic (₹) | 3.36 | 2.80 | +20.0% | 4.85 | −30.7% |
| Net margin (%) | 13.0 | 12.1 | 17.3 |
Consolidated
- Filed with BSE
- 06 Aug 2026, 23:45 IST
- Board meeting
- 06 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Aug 2026, 23:45 IST
- Board meeting
- 06 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE